Lung Cancer
From the Journals
Sharp declines for lung cancer, melanoma deaths fuel record drop in cancer mortality
Reductions in smoking are largely responsible for the lung cancer progress, while immunotherapy and targeted treatments have improved survival in...
From the Journals
New toxicity subscale measures QOL in cancer patients on checkpoint inhibitors
With further validation, the instrument could become an important tool for evaluation of treatment-related toxicity.
From the Journals
Standard-dose RT with concurrent chemo found superior for unresectable NSCLC
An update of the RTOG 0617 trial, now at a median follow-up of 5.1 years, finds that overall survival is better with standard-dose RT versus high-...
From the Journals
Benefits and drawbacks found for risk-based lung cancer screening tools
Modeling indicated risk-based lung cancer screening tools could prevent significantly more lung cancer deaths, but life-year gains were negligible...
News
FDA approves atezolizumab combo as first line for advanced NSCLC
The approval for first-line treatment was based on results of IMpower 130, which demonstrated an overall survival benefit with atezolizumab in...
Feature
Large state disparities seen for lung cancer screening
Lung cancer screening for high-risk individuals remains low.
Feature
Not all lung cancer patients receive treatment
Reasons include metastasis and refusal, and rates by state vary from 8% to 30%, the American Lung Association reports.
Conference Coverage
Neoantigen vaccine appears safe and active in NSCLC
NATIONAL HARBOR, MD. – The vaccine produced only grade 1 adverse events and yielded responses in 7 of 24 patients,...
From the Journals
Lorlatinib induces deep responses in ROS1-positive NSCLC
Among 40 crizotinib-pretreated patients, 14 patients (35%) had an objective response on lorlatinib, with a median duration of response of 13.8...
Conference Coverage
Atezolizumab bests chemo in NSCLC patients with high PD-L1 expression
Atezolizumab provided a 7-month benefit in median overall survival for patients with stage IV non–small cell lung cancer and high PD-L1 expression...